Recipients Announced for 2021 Samyang CRS Award in Honor of Sung Wan Kim for Biomedical Research

Award to be presented at Controlled Release Society 2021 Annual Meeting in July

(CAMBRIDGE, Mass./SEOUL, Korea, April 21, 2021) – Samyang Biopharm USA, Inc. (https://us.samyangbiopharm.com) a global biotech subsidiary of the Samyang Pharmaceuticals Corp. (https://samyangbiopharm.com/eng), announced today that the company has announced that the winners of the “2021 Samyang CRS Award in Honor of Sung Wan Kim” have been unveiled by the Controlled Release Society.

This year’s recipients are Professor Stefaan De Smedt, PhD, Pro-dean of the faculty of Pharmaceutical Sciences, Director of Ghent Research Group on Nanomedicines, Director of Laboratory of General Biochemistry and Physical Pharmacy Ghent University, Belgium and Yoon Yeo, PhD, Professor of Industrial and Physical Pharmacy and Biomedical Engineering, Associate Department Head, Industrial and Physical Pharmacy, Purdue University, USA.

The Award will become an annual presentation to a mid-career scientist in biomedical research who has begun to establish themselves as a leader in the areas of drug discovery and make significant scientific contributions to their area of research.

“Samyang is delighted to honor the 2021 recipients of this distinguished award that reflects the work of the award’s namesake, Sung Wan Kim,” said Hyun Jung Helen Lee, M.D., President and CEO of Samyang Biopharm USA. “The work of Professors Yeo and De Smedt is emblematic of Dr. Kim’s pioneering research and they should feel honored by this wonderful recognition by the Controlled Release Society.”

The Awards will be presented at the 2021 Annual Meeting of the Controlled Release Society in July, 2021.

Sung Wan Kim, Ph.D., was Distinguished Professor of Pharmaceutics and Pharmaceutical Chemistry and Distinguished Professor of Bioengineering at the University of Utah. His subsequent research into drug delivery using biopolymers had an enormous influence on the development of hydrogels, biodegradable drug conjugates, self-regulating drug delivery, and stimuli sensitive polymers. Among his contributions to this field was the design of new polymeric structures capable of carrying genes into cells, which is based on a deep understanding of physio-chemical, synthetic, and biological principles. The successful delivery systems are multifunctional and possess balanced individual contributions providing an optimal composition with outstanding properties. His laboratory also designed many biomaterials for delivery of anticancer drugs. Kim held 38 patents and generated more than $30 million in research funds. In addition, he published more than 500 research papers, co-founded three biotech companies, and established the U of U’s Center for Controlled Chemical Delivery. He was elected to the National Academy of Medicine in 1999 and the National Academy of Engineering in 2003. He retired from the University in 2018.

About the Samyang Award in Honor of Sung Wan Kim

The Controlled Release Society’s Samyang Award in Honor of Sung Wan Kim recognizes a current Controlled Release Society member who has made outstanding contributions in the science of controlled release over a period of not less than 10 years. The nominee must be a current CRS member and must have been a CRS member for not less than the previous five years consecutively. The honoree must be between 41-55 years old as of December 31 in the year the award is presented and present at the CRS annual meeting the year of the award.

The winner of the Samyang Award in Honor of Sung Wan Kim will be selected by a selection committee appointed by the board of directors of the CRS. Samyang Biopharm USA will provide a $10,000 award sponsorship and the award will be presented each year at the at the CRS Annual Meeting, by Hyun Jung Helen Lee, M.D., President and CEO of Samyang Biopharm USA.

About Samyang Biopharm USA, Inc.
Samyang Biopharm USA, a biopharmaceutical company focused on the global development of first-in class biologic therapeutics for oncology and rare disease indications, was established as a subsidiary of Samyang Biopharmaceuticals Corporation (South Korea) in August 2018. The company collaborates with select biotechnology companies, research institutes, hospitals and universities through an “Open Innovation” strategy.  Through collaborations, partnerships and in-licensing, Samyang Biopharm USA seeks to identify promising pre-clinical and early clinical candidates and advance them through clinical development with the objective of improving the lives of patients worldwide.

 

#   #   #

Media Contact:
Paul Kidwell
paulkidwell@comcast.net